Qiagen

Operator of a biotechnology platform intended to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds. The company's platform focuses on developing a single-molecule, massively parallel, de novo next-generation protein sequencing platform, enabling scientists and researchers to develop novel therapeutics and diagnostics and ultimately understand human biology and disease.

Actome specializes in emulsion coupling technology and interactome technology to advance life science research and personalized medicine. The company has developed a proprietary method that allows for the detection of single protein molecules and protein interaction complexes. By translating protein status into DNA barcodes using DNA-labeled antibodies, Actome enables detailed molecular biological research. This innovative approach aids clients in quantifying proteins, analyzing protein interactions, and studying post-translational modifications in biological samples. Through its technologies, Actome contributes to advancements in pharmaceuticals and the development of novel personalized therapies.

NeuMoDx Molecular, Inc. is a molecular diagnostics company focused on developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. Established in 2012 and based in Ann Arbor, Michigan, the company was formerly known as Molecular Systems Corporation before rebranding in April 2013. As of September 2020, NeuMoDx operates as a subsidiary of QIAGEN N.V. Its innovative products aim to enhance the efficiency and accuracy of molecular testing, contributing to better patient outcomes in various healthcare settings.

N-of-One, Inc. is a molecular decision support company that specializes in the interpretation of molecular test results for cancer care. It provides clinicians with detailed insights into the biological relevance of diseases, clinical evidence, associated therapies, and references. The company interprets next-generation sequencing (NGS) data from solid and hematological tumors, as well as circulating tumor cells and DNA. N-of-One delivers a clinical interpretation report called PrecisionInsights, which covers 15-20 gene NGS panels, summarizing clinical and scientific evidence for each biomarker relevant to specific cancer subtypes and listing potential therapeutic options. Additionally, it offers TRIALMATCH, a solution for matching patients to suitable clinical trials based on their individual profiles. N-of-One serves various stakeholders, including commercial and hospital laboratories and precision medicine programs. Founded in 2007 and based in Lexington, Massachusetts, N-of-One operates as a subsidiary of QIAGEN N.V. since January 2019.

Parsagen Diagnostics is comprised of a team of passionate and driven leaders who have a proven ability to bring a product from conception through commercialization in multiple global markets. As they expand their presence in the US & abroad, they are looking for people who exhibit flexibility under pressure, who have a proclivity to seek & approach challenges with optimism and grit, and who can identify areas of need and contribute to their ultimate fulfillment.

ArcherDX, Inc. is a genomics company based in Boulder, Colorado, focused on advancing molecular pathology through next-generation sequencing technology. Established in 2013, the company develops and commercializes a range of research products, including DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex, and RNA-based Immunoverse, aimed at optimizing therapy and monitoring cancer. ArcherDX also creates in-vitro diagnostic products and offers customizable assay design services to clinical and biopharmaceutical clients, enabling the development of new applications tailored to specific biomarker targets. The Archer platform utilizes proprietary Anchored Multiplexed PCR (AMP™) chemistry and sophisticated bioinformatics to enhance genetic mutation detection significantly. The company's products and services are utilized by academic and reference laboratories, biopharmaceutical firms, and contract research organizations, with ongoing efforts to gain regulatory approval for various companion diagnostic assays. As of October 2020, ArcherDX operates as a subsidiary of Invitae Corporation.

STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.

OmicSoft Corporation specializes in bioinformatics and software solutions for next-generation sequencing and cancer genomics. Founded in 2007 and based in Cary, North Carolina, the company develops tools for biomarker data management, visualization, and analysis, catering primarily to pharmaceutical and biotech companies, universities, hospitals, and research institutes. Its product offerings include Array Suite, which encompasses bioinformatics tools for quality control, alignment, and data analysis; various genomic databases like CVMLand, ImmunoLand, and OncoLand for exploring cardiovascular, immune, and cancer genomics datasets; and GeneticsLand, which focuses on the storage and integration of genetic data. OmicSoft's solutions facilitate efficient data management and comparison with extensive public datasets, aiding researchers in discovery and translational research. In 2017, OmicSoft became a subsidiary of QIAGEN N.V.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

MO BIO Laboratories, Inc. provides DNA and RNA isolation and protein extraction tools. The company engages in developing and manufacturing new products for life science research. It also provides soil, stool, and microbial nucleic acid purification services. In addition, the company provides certifications and sterility assurance services to various plastic and medical device suppliers.

Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

BIOBASE is a provider of expert-curated biological databases, software and services for the life sciences.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

CLC bio is the world's leading bioinformatics solution provider focusing on analyzing data from all major high-throughput sequencing machines, such as instruments coming from Illumina, Applied Biosystems (LIFE Technologies), Roche 454, Helicos, or Sanger.

Ingenuity Systems, founded in 1998 by Stanford graduate students, specializes in knowledge management solutions for the life sciences sector. The company develops innovative software that empowers researchers to search, explore, visualize, and analyze complex biological and chemical data related to genes, proteins, and small molecules. Central to Ingenuity's offerings is the Ingenuity Knowledge Base, a comprehensive repository containing millions of modeled relationships among various biological entities, which is meticulously reviewed for accuracy. Key products include Ingenuity Pathway Analysis (IPA), which integrates and analyzes diverse omics data to provide insights into molecular interactions and disease processes, and Ingenuity iReport, designed for rapid interpretation of gene expression data. Additionally, Ingenuity Variant Analysis aids researchers in identifying significant genetic variants using both published evidence and personal expertise in disease biology. Headquartered in Redwood City, California, Ingenuity operates offices in several countries, including Germany, Switzerland, France, the United Kingdom, and Japan, enhancing its global reach within the life sciences community.

Drug Response Dx is based in Hennigsdorf, Germany and was founded in February 2012 by Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner and Dr. Joachim Rautter. The biomarker set is prevalidated; the biochemicals and test samples are present. The proof of concept in serums from RA patients is established.

Intelligent Bio-Systems, founded in 2005 by Drs. Steven J. Gordon and Jingyue Ju, focuses on the commercialization of advanced DNA sequencing systems. The company aims to enhance the speed and reduce the cost of generating sequence data, making its technology applicable in various fields, including research, clinical applications, and DNA resequencing. Its systems are particularly valuable for cancer and HIV/AIDS applications, allowing customers to achieve low-cost throughput sequencing while ensuring high-quality data. Dr. Gordon's background includes founding Intelligent Automation Systems, which contributed significantly to the Human Genome Project, while Dr. Ju is noted for her pioneering work on fluorescent energy transfer dyes that are integral to many electrophoresis-based sequencing technologies.

AmniSure International specializes in the development and marketing of the AmniSure diagnostic test, designed to detect rupture of fetal membranes (ROM) in pregnant women. The test, which has received FDA clearance and is approved for use in various international markets, utilizes proprietary technology to identify small amounts of amniotic fluid in vaginal discharge. This one-step, minimally invasive test provides results in just minutes at the point of care, boasting an accuracy rate near 99%, significantly surpassing traditional testing methods. AmniSure is recognized as a gold-standard test in pregnancy care and is reimbursable under most U.S. state Medicaid plans, making it an essential tool for healthcare professionals in managing pregnancy complications.

Xagenic Inc. is a Toronto-based molecular diagnostics company focused on developing innovative technology for decentralized and rapid diagnostic testing. The company aims to enhance patient care by enabling on-demand, near-patient molecular testing, which allows clinicians to make informed treatment decisions during the initial consultation. Xagenic's technology facilitates rapid, enzyme-free detection of nucleic acids from clinical samples, yielding results in just 20 minutes. By commercializing a simple and fully automated platform, Xagenic is positioned to revolutionize diagnostic testing by enabling it to be conducted outside of traditional clinical laboratories. The company is also working on tests for infectious diseases that provide clinically actionable results in a timely manner, thereby improving overall healthcare efficiency and reducing costs.

Cellestis is manufactures and markets QuantiFERON products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses using whole blood samples.

Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.

ESE GmbH is a company that was acquired by Qiagen in 2010.

SABiosciences Corporation, founded in 1998, is a privately held biotechnology company. Their founders envisioned a new, more systematic approach to biological research in the post-genomic era. Today, they have developed a portfolio of research tools that merge the benefits of hypothesis-driven and discovery-based research.

DxS (now a Qiagen company) is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, DxS will support the development and sales of targeted cancer therapies by providing companion diagnostic products and services. Since its founding in 2001, DxS has experienced considerable growth and firmly established itself as a leader in companion diagnostics, having recently secured deals with leading healthcare companies such as Amgen, Boehringer Ingelheim, and AstraZeneca. In addition, DxS has an exclusive agreement with Roche Diagnostics for the global distribution of its diagnostic products. DxS has a portfolio of cancer mutation products including both diagnostic and assays for research use. The TheraScreen® range of CE-marked (IVD) diagnostic* kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS currently produce two diagnostic kits, TheraScreen K-RAS and TheraScreen EGFR29. The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS was acquired by Qiagen (NASDQ : QGEN) and continues to operate from the heart of Manchester’s Technology Quarter in the UK.

Explera s.r.l. is a company that specializes in the import, manufacture, and marketing of products for molecular biology research laboratories, both in Italy and internationally. The company provides a range of laboratory instruments, including DNA sequencing equipment, thermal cyclers, ultra-compact thermal cycling devices, and photo-documentation systems. Additionally, Explera offers various small laboratory tools such as shakers, rotators, multi shakers, shakers-incubators, centrifuges, vortexes, thermostats, water baths, dry blocks, and magnetic stirrers, as well as biohazard and PCR cabinets. Through its diverse product offerings, Explera supports the needs of research and medical laboratories in advancing molecular biology studies.

Corbett Life Science Pty., Ltd. designs, manufactures, and internationally distributes instrumentation systems for the life sciences. The company offers Rotor-Gene, a DNA amplification system; CAS-1200, a PCR setup robot; the CAS-4200 and CAS-4800 precision liquid handling workstations; X-tractor Gene, a nucleic acid extraction system; Palm-Cycler, a gradient thermal cycler with a palmtop computer interface; and CorProtocol, a reagent for DNA preparation on the X-tractor Gene system. It also offers Vapor-Lock, a PCR encapsulation barrier; high resolution melt, a instrumentation that provides acute thermal and optical precision, high speed data acquisition, and new software tools for data analysis used for gene scanning, sequence matching, genotyping, quantitative allelotyping, and quantitative DNA methylation analysis; and the Gel-Scan 3000, a automated DNA sequencer and fragment analyzer. In addition, the company provides automation for RNA/DNA extraction, liquid handling robotics, and real time DNA amplification and analysis to laboratories across the United States. It has operation in North America, South America, the United Kingdom, Europe, the Middle East, Africa, Asia, and Oceania. The company has a strategic partnership with Sigma-Aldrich. Corbett Life Science Pty. Ltd. was formerly known as Bio-Molecular Holdings Pty. Limited. Corbett Life Science Pty., Ltd. was founded in 1988 and is based in Sydney, Australia. It has operating units in Sydney and Brisbane, Australia; Cambridgeshire, the United Kingdom; and San Francisco, the United States. As of July 1, 2008, Corbett Life Science Pty., Ltd. operates as a subsidiary of Qiagen NV.

eGene, Inc. is a biotechnology company, engages in developing, manufacturing, and marketing analytical systems and reagents for the genotyping market. It uses capillary electrophoresis, microfluidics, reagents liquid handling, and automation technologies to create a DNA/RNA analysis system for biological materials and life sciences testing. The company offers HDA-GT12 genetic analyzer, which uses capillary electrophoresis-based technology for DNA/RNA separation. Its HDA-GT12 system is used to detect, quantify, identify, and characterize biological organisms, as well as to automate the routine and non-routine laboratory and industrial procedures.

Digene Corporation is develops, manufactures, and markets proprietary gene-based diagnostic tests for the screening, monitoring, and diagnosis of human diseases with a focus on women’s cancers and infectious diseases worldwide. The company primarily offers human papillomavirus (HPV) testing products, which are FDA-approved tests for the detection of HPV, are a reproducible, objective test for the primary cause of cervical cancer. Its primary product is The Digene HPV Test, a FDA-approved test for HPV, the primary cause of cervical cancer.

Genaco Biomedical Products, Inc. develops and markets medical genetic products and services in China. The company offers prenatal screening; neonatal screening; commercial kits for prenatal screening and diagnosis of common genetic diseases; cytogenetic equipment; molecular genetics equipment, such as gel boxes and power supplies; and general laboratory supplies. It distributes its products through distributors and medical genetic centers.

Gentra Systems, Inc. develops and markets nucleic acid purification reagents and instruments for clinical and clinical research laboratories. The company’s DNA and RNA purification products include Generation Kits, which provide DNA purification for small samples; Purescript kit that provides a non-toxic method for purifying RNA; Autopure ls instrument for processing samples, by purifying Puregene-quality DNA from blood samples; and Versagene RNA.

Shenzhen PG Biotech Co, Ltd., is a molecular biology company, engages in the development, manufacture, and marketing of research and clinic diagnosis reagents and instruments. Its integrated services include technical consultation, product introduction, and customer order upon request, as well as after-sale service. The company serves in the areas of scientific fields, including molecular biology, cell biology, genetics, microbiology, and management.

Nextal Biotechnologies specializes in the production of screens and plates for protein crystallization, which is a crucial component in structural biology studies and structure-based drug design. Based in Holland, Ohio, the company offers products tailored to meet the experimental needs of crystallization, including plates with grease-free, independent screwable supports. As of January 2020, Nextal Biotechnologies operates as a subsidiary of CalibreScientific Inc.

artus GmbH is a biotechnology company specialized in the development, production and sale of diagnostic kits based on modern DNA analytical procedures. The main focus of these detection procedures is PCR and real-time PCR technology. The detection systems are mainly used in identifying infectious agents, in pharmacogenomics and in veterinary diagnostics.

Molecular Staging, Inc., a life sciences tool company, develops technologies for the detection and measurement of proteins and nucleic acids. It provides technologies for proteomics, genomics, pharmacogenomics, and diagnostics applications. The company’s products and services include protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins; whole-genome amplification that allows DNA samples as resources, enabling researchers to return to them for new tests or confirmatory diagnoses; and multiplexed diagnostics that enable earlier detection of disease.

Xeragon is develops and markets products and services focusing on oligoribonucleotides (RNA). The company’s TOM-Amidite technology allows chemical synthesis of RNA and its siRNA technology helps in RNA synthesis and gene silencing. Xeragon’s products and services are used by RNA scientists in the fields of biopharmaceuticals, diagnostics, therapeutics, and structural studies.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.